Craig P. Carden

3.2k total citations · 1 hit paper
18 papers, 2.1k citations indexed

About

Craig P. Carden is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Craig P. Carden has authored 18 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Craig P. Carden's work include PARP inhibition in cancer therapy (4 papers), DNA Repair Mechanisms (3 papers) and Cancer Genomics and Diagnostics (3 papers). Craig P. Carden is often cited by papers focused on PARP inhibition in cancer therapy (4 papers), DNA Repair Mechanisms (3 papers) and Cancer Genomics and Diagnostics (3 papers). Craig P. Carden collaborates with scholars based in United Kingdom, Australia and United States. Craig P. Carden's co-authors include Stan B. Kaye, Timothy A. Yap, Timothy A. Yap, Johann S. de Bono, Christina Messiou, Charlie Gourley, Jacques De Grève, Jan H.M. Schellens, John Stone and Susan Shanley and has published in prestigious journals such as Journal of Clinical Oncology, Nature reviews. Cancer and Cancer Research.

In The Last Decade

Craig P. Carden

18 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

2010 745 citations Peter C.C. Fong, Timothy A. Yap et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Craig P. Carden United Kingdom	13	1.1k	1.1k	536	413	292	18	2.1k
E. Berns Netherlands	23	921 0.8×	1.0k 0.9×	294 0.5×	763 1.8×	168 0.6×	42	2.0k
Yvette Drew United Kingdom	22	1.8k 1.5×	1.4k 1.2×	625 1.2×	233 0.6×	170 0.6×	68	2.3k
Sharad Ghamande United States	22	770 0.7×	579 0.5×	476 0.9×	216 0.5×	230 0.8×	114	1.7k
Emma Dean United Kingdom	29	1.4k 1.3×	1.8k 1.6×	175 0.3×	436 1.1×	390 1.3×	132	2.7k
Iván Díaz-Padilla United States	21	728 0.6×	634 0.6×	260 0.5×	392 0.9×	273 0.9×	53	1.4k
Euan Macpherson United Kingdom	9	2.3k 2.0×	1.3k 1.2×	1.1k 2.0×	398 1.0×	455 1.6×	13	3.0k
Jozien Helleman Netherlands	22	566 0.5×	1.1k 1.0×	303 0.6×	670 1.6×	457 1.6×	42	2.0k
Carmela Pisano Italy	26	706 0.6×	532 0.5×	862 1.6×	292 0.7×	261 0.9×	95	1.9k
Hiroaki Itamochi Japan	36	1.1k 1.0×	1.8k 1.7×	1.3k 2.3×	649 1.6×	313 1.1×	139	3.6k
Giorgio Valabrega Italy	28	1.8k 1.6×	946 0.9×	394 0.7×	497 1.2×	490 1.7×	115	2.8k

Countries citing papers authored by Craig P. Carden

Since Specialization

Citations

This map shows the geographic impact of Craig P. Carden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Craig P. Carden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Craig P. Carden more than expected).

Fields of papers citing papers by Craig P. Carden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Craig P. Carden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Craig P. Carden. The network helps show where Craig P. Carden may publish in the future.

Co-authorship network of co-authors of Craig P. Carden

This figure shows the co-authorship network connecting the top 25 collaborators of Craig P. Carden. A scholar is included among the top collaborators of Craig P. Carden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Craig P. Carden. Craig P. Carden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Jones, Robin L., Edward S. Kim, Pilar Nava-Parada, et al.. (2014). Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors. Clinical Cancer Research. 21(4). 693–700. 77 indexed citations

Carden, Craig P., Adam Stewart, Emma Kipps, et al.. (2012). The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. Molecular Cancer Therapeutics. 11(7). 1609–1617. 81 indexed citations

Nathan, Paul, Martin Zweifel, Anwar R. Padhani, et al.. (2012). Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer. Clinical Cancer Research. 18(12). 3428–3439. 153 indexed citations

Rizzo, Siân, Paul Mellor, Wei Dai, et al.. (2011). Ovarian Cancer Stem Cell–Like Side Populations Are Enriched Following Chemotherapy and Overexpress EZH2. Molecular Cancer Therapeutics. 10(2). 325–335. 171 indexed citations

Yap, Timothy A., Shahneen Sandhu, Craig P. Carden, & Johann S. de Bono. (2011). Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA A Cancer Journal for Clinicians. 61(1). 31–49. 163 indexed citations

Fong, Peter C.C., Timothy A. Yap, David S. Boss, et al.. (2010). Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. Journal of Clinical Oncology. 28(15). 2512–2519. 745 indexed citations breakdown →

Brunetto, André T., et al.. (2010). Modest Reductions in Dose Intensity and Drug-Induced Neutropenia have No Major Impact on Survival of Patients with Non-small Cell Lung Cancer Treated with Platinum-Doublet Chemotherapy. Journal of Thoracic Oncology. 5(9). 1397–1403. 19 indexed citations

Carden, Craig P., Timothy A. Yap, & Stan B. Kaye. (2010). PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Current Opinion in Oncology. 22(5). 473–480. 30 indexed citations

Carden, Craig P., Alison Reid, Susana Miranda, et al.. (2010). Abstract 788: Correlation of elevated phosphorylated / total AKT ratio, chemoresistance and survival in ovarian cancer ascites samples. Cancer Research. 70(8_Supplement). 788–788. 1 indexed citations

10.

Yap, Timothy A., Craig P. Carden, & Stan B. Kaye. (2009). Beyond chemotherapy: targeted therapies in ovarian cancer. Nature reviews. Cancer. 9(3). 167–181. 405 indexed citations

11.

Carden, Craig P., Debashis Sarker, Sophie Postel‐Vinay, et al.. (2009). Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug Discovery Today. 15(3-4). 88–97. 52 indexed citations

12.

Gedrich, Richard, Andrew Stephens, Elizabeth Buck, et al.. (2009). Abstract A46: Pharmacodynamic biomarkers for OSI-906, an insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in cancer patients with advanced solid tumors. Molecular Cancer Therapeutics. 8(12_Supplement). A46–A46. 2 indexed citations

13.

Carden, Craig P., Roshan Agarwal, Frank Saran, & Ian Judson. (2008). Eligibility of patients with brain metastases for phase I trials: time for a rethink?. The Lancet Oncology. 9(10). 1012–1017. 16 indexed citations

14.

Carden, Craig P., James Larkin, & Mark Rosenthal. (2008). What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro-Oncology. 10(4). 624–630. 60 indexed citations

15.

Yap, Timothy A., Craig P. Carden, Gerhardt Attard, & Johann S. de Bono. (2008). Targeting CYP17: established and novel approaches in prostate cancer. Current Opinion in Pharmacology. 8(4). 449–457. 83 indexed citations

16.

Arkenau, Hendrik‐Tobias, Craig P. Carden, & Johann S. de Bono. (2008). Targeted agents in cancer therapy. Medicine. 36(1). 33–37. 6 indexed citations

17.

Carden, Craig P., Michael Jefford, & Mark Rosenthal. (2007). Information about cancer clinical trials: An analysis of Internet resources. European Journal of Cancer. 43(10). 1574–1580. 12 indexed citations

18.

Carden, Craig P. & Mark Rosenthal. (2007). Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer. Asia-Pacific Journal of Clinical Oncology. 3(4). 187–198. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact